Glecirasib Generates Durable Responses in Pretreated Advanced KRAS G12C+ NSCLC
Glecirasib elicited responses and demonstrated a manageable safety profile in patients with pretreated advanced NSCLC harboring KRAS G12C mutations.
Source: onclive.com
Resectable Nsclc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Resectable Nsclc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Resectable Nsclc Today - Breaking & Trending Today
Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence
The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC.
Source: onclive.com
#VisualAbstract: Perioperative Durvalumab for Resectable Non-Small-Cell Lung Cancer
Click to read this study in NEJM. VA design by Bryan Sun. ©2023 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute
Source: 2minutemedicine.com